About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Effect of BIBW 2948 BS in COPD

NCT00423137·6 sites·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

Boehringer Ingelheim

Age

40–70

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

COPD smokers
ages between 40 and 70

You may not be if

Significant other diseases
abnormal hematology
abnormal liver function
psychiatric disorders
pulmonary obstruction
asthma, allergic rhinitis
dependance on oxygen
patients with history of myocardial infarction
patients with history of cancer
women of child bearing potential
antiplatelet or anticoagulation therapy

The record

StatusCompleted

PhasePhase 2

Taking part48

StartedJan 2007

UpdatedNov 19, 2021

Conditions

Pulmonary Disease, Chronic Obstructive Bronchitis, Chronic

Where6

1219.5.03 Boehringer Ingelheim Investigational Site
Birmingham, Alabama, United States
1219.5.01 Boehringer Ingelheim Investigational Site
San Francisco, California, United States
1219.5.02 Boehringer Ingelheim Investigational Site
Denver, Colorado, United States

Clareo Health | Effect of BIBW 2948 BS in COPD